Jan 09,2018

Ascensia Diabetes Care Expands Strategic Alliance with Insulet Corporation by Signing Commercial Agreement

Ascensia Diabetes Care today announced it has expanded the scope of its strategic alliance with Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology, by signing a global commercial agreement. This follows the worldwide non-exclusive development agreement that Ascensia announced in June 2017 to connect its CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) with Insulet’s next-generation Omnipod System (Omnipod DASH).

COLLABORATION PARTNERSHIP

#connected device

#bgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 25,2018

Sweetch Develops AI Platform That Predicts Individual’s Risk For Developing A Metabolic Syndrome Related Disease

Sweetch is an Artificial Intelligence-based platform aimed at reducing the risk and improving the outcomes of Metabolic Syndrome diseases – Diabetes, Pre-Diabetes, Hypertension, Pre-Hypertension, Obesity, and Hyperlipidemia. Find the recent interview with Dana Chanan CEO at Sweetch here.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Jan 29,2018

Insulet Corporation to Announce Fourth Quarter and Full Year 2017 Financial Results on February 21, 2018

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year of 2017 on February 21, 2018 after the close of the financial markets.

View Analyst & Ambassador Comments
Go to original news
Jan 31,2018

Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program

Nemaura Medical Inc., a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes today announced positive summary data for its sugarBEAT® European clinical trial program.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 05,2018

JDRF partners with Cam Med for development of patch-like insulin pump

The Juvenile Diabetes Research Foundation (JDRF) and Massachusetts-based Cam Med, a company specializing in microfluidic-based drug delivery technologies, announced a partnership today focused on development of a thin, flexible, patch-based insulin pump for artificial pancreas systems.

COLLABORATION PARTNERSHIP

#product & service

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 07,2018

Study: Cardiogram's DeepHeart detects diabetes through smartwatches

A new study from Cardiogram suggests that ordinary wearables like Fitbit and Apple watches can detect diabetes and other medical conditions when integrated with Cardiogram’s DeepHeart app.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 14,2018

Glooko receives FDA clearance for mobile insulin titration tool

Digital diabetes care company Glooko announced today that its Mobile Insulin Dosing System (MIDS) — an app-driven tool that recommends insulin dose adjustments using data collected directly from a patient’s blood glucose meter — has been cleared by the FDA.

REGULATORY FDA

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 15,2018

DreaMed Diabetes has received a CE Mark for its Type 1-focused clinical decision support (CDS) platform

DreaMed Diabetes has received a CE Mark for its Type 1-focused clinical decision support (CDS) platform, Advisor Pro. The tool’s algorithms process data from a number of connected diabetes management devices to provide a personalized insulin dosing treatment plan. The software achieved similar glycemic control when compared to medical experts during pilot studies, according to DreaMed, and a multi-center trial run with Glooko (which announced a similar approval yesterday) is currently underway.

REGULATORY CE MARK
View Analyst & Ambassador Comments
Go to original news
Feb 15,2018

FareWell changes name to Better Therapeutics, sees 0.8 percent A1c reduction in small study

San Francisco-based FareWell is changing its name to Better Therapeutics, a rebranding that reflects the company’s shift in focus from weight loss and disease prevention to digital therapeutics to treat chronic diseases. To punctuate that shift, Better Therapeutics is announcing the name change on the same day as the publication of a study in the Journal of Medical Internet Research that demonstrates the company’s technology can reduce HbA1c in people with Type 2 diabetes.

CLINICAL STUDY

#mobile app

#dtx

View Analyst & Ambassador Comments
Go to original news
Feb 20,2018

Roche’s Accu-Chek diabetes management app receives its fifth FDA recall

Roche’s Accu-Chek Connect Diabetes Management App has hit yet another snag with the FDA. On February 15, the agency issued a Class 2 Device Recall for certain software versions of the app due to a bug that could lead users to self-administer inappropriate doses of insulin.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES